{
    "Part 1": {
        "Part 1": "Identification of Differentially Expressed Genes (DEGs) in Liposarcoma",
        "step 1": {
            "implementation details": "Use GEO2R to identify DEGs from the selected datasets. Load datasets GSE21122 (tissue type: 'Soft-tissue sarcoma', disease status: 'Liposarcoma'), GSE159659 (samples: 'dedifferentiated liposarcoma'), GSE30929 (samples: 'primary liposarcoma'), and GSE159848 (samples: 'mixoid liposarcoma'). Normalize data using the Robust Multi-array Average (RMA) method. Set the p-value threshold for DEGs at <0.05 and the fold-change threshold at >2. After normalization, extract the list of DEGs, including their associated p-values and fold changes. Detailed instructions for using GEO2R: navigate to the GEO2R tool on the GEO website, select the datasets, and follow the prompts to normalize and analyze the data. Include screenshots for clarity if needed.",
            "Reference Source": {
                "id1": {
                    "report_id1": [
                        11277418
                    ],
                    "report_id2": [
                        7458655
                    ]
                },
                "id2": {
                    "report_id1": [
                        11277418
                    ],
                    "report_id2": [
                        7458655
                    ]
                }
            }
        },
        "step 2": {
            "implementation details": "Conduct functional annotation of the identified DEGs using the Database for Annotation, Visualization, and Integrated Discovery (DAVID). Input the list of DEGs into DAVID and select 'Homo sapiens' as the background. Analyze the biological process, cellular component, and molecular function categories. Set the significance threshold for annotations at a p-value <0.05. Document the top 10 enriched terms for each category and their corresponding p-values. Include specific instructions for using DAVID, such as how to upload gene lists and interpret results, and suggest alternative annotation tools like Enrichr if initial results are unsatisfactory.",
            "Reference Source": "Cite relevant literature that discusses gene ontology and pathway analysis, along with the DAVID user guide."
        },
        "step 3": {
            "implementation details": "Perform pathway enrichment analysis using the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. Input the DEGs from the previous steps into the KEGG pathway analysis tool. Set the significance threshold for pathways at p-value <0.05. Document the top 10 significantly enriched pathways with their respective p-values and the number of DEGs involved in each pathway. Include clear instructions for using the KEGG database, such as how to input data and interpret the outputs. Suggest alternative pathway analysis tools like Reactome if necessary.",
            "Reference Source": "Cite relevant literature that discusses pathways associated with liposarcoma, as well as the KEGG database documentation."
        },
        "step 4": {
            "implementation details": "Correlate DEGs with immune response mechanisms by researching literature that links specific DEGs to immune responses in liposarcoma. Identify key immune-related genes from the DEG list and summarize their roles based on existing studies. Discuss the implications of these correlations in terms of potential therapeutic strategies targeting the immune microenvironment in liposarcoma. Provide references to key studies and consider suggesting alternative approaches for correlation if needed.",
            "Reference Source": {
                "id1": {
                    "report_id1": [
                        11277418
                    ],
                    "report_id2": [
                        7458655
                    ]
                },
                "id2": {
                    "report_id1": [
                        11277418
                    ],
                    "report_id2": [
                        7458655
                    ]
                }
            }
        },
        "step 5": {
            "implementation details": "Conclude the protocol with a summary that encapsulates the findings and implications of the analysis. Highlight the significance of the identified DEGs and their potential roles in the immune microenvironment of liposarcoma. Discuss how these findings can inform future research directions and therapeutic strategies for liposarcoma.",
            "Reference Source": "Include general references that summarize the implications of DEGs in cancer and potential future research directions."
        }
    },
    "Part 2": {
        "Part 2": "Immune Landscape Analysis in Liposarcoma",
        "step 1": {
            "implementation details": "The first step involves analyzing immune checkpoint and membrane marker expression across liposarcoma samples using RNA sequencing data from GSE202361 and GSE243904. Focus will be placed on immune checkpoint genes like PD-1, PD-L1, CTLA-4, and others. Expression levels of these markers will be quantified using R software with the 'DESeq2' package for normalization and statistical analysis. The p-value threshold for significance will be set at <0.05, and false discovery rate (FDR) adjustments will be applied using the Benjamini-Hochberg method. A heatmap will be generated using the 'pheatmap' package in R to visualize the expression patterns of these markers across the samples.",
            "Reference Source": {
                "id1": {
                    "GSE202361": [
                        "Immune checkpoint expression analysis"
                    ],
                    "GSE243904": [
                        "Immune checkpoint expression analysis"
                    ]
                },
                "id2": {
                    "GSE202361": [
                        "Immune checkpoint expression analysis"
                    ],
                    "GSE243904": [
                        "Immune checkpoint expression analysis"
                    ]
                }
            }
        },
        "step 2": {
            "implementation details": "In this step, we will estimate immune cell proportions using CIBERSORTx. The bulk RNA sequencing data from GSE202361 and GSE243904 will be uploaded to the CIBERSORTx web portal. We will select the leukocyte signature matrix version 2.0. The analysis will be run using the default parameters, ensuring batch correction is applied if necessary. If any outliers are detected, they will be excluded from the analysis. The output will include proportions of various immune cell types within each tumor sample and will be exported for further analysis.",
            "Reference Source": "CIBERSORTx analysis based on bulk RNA sequencing data from GSE202361 and GSE243904"
        },
        "step 3": {
            "implementation details": "This step will correlate immune cell distributions with differentially expressed genes (DEGs) identified in Part 1. The immune cell proportions obtained from CIBERSORTx will be compared with the expression levels of DEGs using correlation analysis performed in R. Statistical methods such as Pearson or Spearman correlation coefficients will be used to assess the relationship between immune cell types and DEGs. Additionally, patient outcomes (e.g., survival data) will be correlated with immune cell distributions and DEGs to assess their prognostic value using Kaplan-Meier survival analysis.",
            "Reference Source": "Correlation analysis based on DEGs from Part 1 and immune cell proportions from CIBERSORTx"
        },
        "step 4": {
            "implementation details": "In this step, we will discuss the implications of the findings for immunotherapy strategies tailored to liposarcoma. Specific examples of immune checkpoints, such as PD-1 and CTLA-4, will be highlighted based on their expression levels and correlation with immune cell types. The discussion will focus on how these checkpoints can serve as therapeutic targets and the potential benefits of combination therapies involving immune checkpoint inhibitors and other treatments, referencing current literature on immunotherapy in sarcomas.",
            "Reference Source": "Discussion based on findings from steps 1 to 3 and relevant literature"
        },
        "step 5": {
            "implementation details": "This final step involves characterizing immune cell populations and their functional implications in the tumor microenvironment. A detailed analysis will be conducted on the immune cell subpopulations identified in step 2, focusing on their functional roles, such as cytotoxicity, regulatory functions, and cytokine production. This characterization will be integrated with the findings from the DEG analysis to provide insights into how immune cell composition may influence tumor progression and response to therapies, including potential therapeutic implications.",
            "Reference Source": "Characterization based on immune cell proportions from CIBERSORTx and functional analysis of DEGs"
        }
    },
    "Part 3": {
        "Part 3": "RNA Sequencing and Differential Expression Analysis",
        "step 1": {
            "implementation details": "Perform quality control on RNA sequencing data by using FastQC (version 0.11.9) to assess the quality of the raw sequencing reads. Analyze key metrics such as Phred quality scores (with a cutoff of 20), GC content, and the presence of adapter sequences. Afterward, use MultiQC (version 1.9) to compile the results from FastQC for easier assessment of quality across all samples. Remove low-quality reads and trim adapter sequences using Trimmomatic (version 0.39) with the following parameters: LEADING:20, TRAILING:20, SLIDINGWINDOW:4:20, MINLEN:50. Store the cleaned reads in a designated directory for further analysis. Utilize datasets GSE21122, GSE159659, GSE30929, and GSE159848 for quality control assessment.",
            "Reference Source": {
                "10773028": {
                    "step_id1": [
                        "Quality Control of RNA sequencing data"
                    ]
                },
                "11277418": {
                    "step_id1": [
                        "Quality Control of RNA sequencing data"
                    ]
                }
            }
        },
        "step 2": {
            "implementation details": "Conduct differential gene expression analysis using DESeq2 (version 1.30.1) on the cleaned RNA sequencing data. Load the libraries and the data into R. Prepare the count matrix using the cleaned reads and create a DESeqDataSet object, specifying the design formula to account for experimental conditions (e.g., liposarcoma vs. normal tissue). Run the DESeq function on the DESeqDataSet object, applying default settings. Extract the results using the results function with an adjusted p-value cutoff of 0.05 to identify significantly differentially expressed genes (DEGs) between liposarcoma and normal tissue samples. Save the results in a CSV file for further analysis. The analysis will incorporate data from the GSE21122 and GSE30929 datasets.",
            "Reference Source": "Reference source for Step 2"
        },
        "step 3": {
            "implementation details": "Perform gene set enrichment analysis (GSEA) to identify relevant pathways and biological processes associated with the identified DEGs. Utilize the clusterProfiler (version 3.18.1) R package to run GSEA. Input the list of DEGs ranked by their log2 fold change and p-values. Use the KEGG and GO databases for pathway analysis, ensuring to set the significance threshold at an adjusted p-value of less than 0.05. Visualize the results with dot plots and enrichment plots to illustrate enriched pathways and their significance. Save the enriched pathways results in a designated directory for reporting. Datasets used for GSEA include the results from the previous DESeq2 analysis.",
            "Reference Source": "Reference source for Step 3"
        }
    },
    "Part 4": {
        "Part 4": "Characterization of Immune Cell Infiltration Using CIBERSORT",
        "step 1": {
            "implementation details": "Begin by preparing the RNA sequencing data from liposarcoma samples. Use the RNA sequencing datasets GSE202361, GSE205492, and GSE243904, which contain transcriptomic information relevant to liposarcoma. Normalize the data using the TPM (Transcripts Per Million) normalization method to ensure comparability across samples. Handling of missing values should be performed through imputation or exclusion, depending on the extent of missingness. Once normalized, extract the gene expression matrix, focusing particularly on immune-related genes. Ensure that the matrix dimensions match the expected input format for CIBERSORT, which requires gene symbols as rows and samples as columns.",
            "Reference Source": {
                "id1": {
                    "GSE202361": [
                        "RNA sequencing data on immune checkpoint blockade in liposarcoma"
                    ],
                    "GSE205492": [
                        "RNA sequencing analysis of NK cells, T cells, and tumors from soft tissue sarcoma"
                    ],
                    "GSE243904": [
                        "Antitumor effects of PRMT5 inhibition in sarcomas (RNA-seq)"
                    ]
                },
                "id2": {
                    "GSE202361": [
                        "RNA sequencing data on immune checkpoint blockade in liposarcoma"
                    ],
                    "GSE205492": [
                        "RNA sequencing analysis of NK cells, T cells, and tumors from soft tissue sarcoma"
                    ],
                    "GSE243904": [
                        "Antitumor effects of PRMT5 inhibition in sarcomas (RNA-seq)"
                    ]
                }
            }
        },
        "step 2": {
            "implementation details": "Run CIBERSORT using the prepared immune-related gene expression matrix as input. Set the parameter for the signature matrix to the LM22 gene signature file provided by CIBERSORT, which contains 547 immune cell-specific gene expression profiles. Adjust the number of permutations to 100 to ensure robust statistical validation. Specify the output format to include estimated cell types and their respective proportions within each liposarcoma sample. After execution, save the results as a CSV file for further analysis. The output will be used to correlate immune cell populations with clinical parameters in subsequent steps.",
            "Reference Source": "CIBERSORT User Manual and documentation"
        },
        "step 3": {
            "implementation details": "Analyze the CIBERSORT output to correlate immune cell type distributions with clinical parameters such as patient prognosis and treatment outcomes. Use statistical analysis methods (e.g., Kaplan-Meier survival analysis and log-rank tests) to evaluate the relationship between specific immune cell populations and patient survival rates. Additionally, integrate these findings with previously identified differentially expressed genes (DEGs) from Part 1 of the experiment to assess how immune cell infiltration impacts gene expression profiles related to immune response mechanisms. This integration will help refine the understanding of the immune landscape in liposarcoma and guide potential therapeutic strategies.",
            "Reference Source": "Kaplan-Meier survival analysis literature and statistical analysis methods"
        }
    },
    "Part 5": {
        "Part 5": "Integration of Single-Cell Sequencing Data",
        "step 1": {
            "implementation details": "Obtain single-cell sequencing data from the relevant dataset. The dataset to be used is GSE205492, which includes RNA sequencing analysis of NK cells, T cells, and tumor from matched soft tissue sarcoma and peripheral blood. Download the dataset from GEO and preprocess the data to remove low-quality cells and unwanted sources of variation. Perform quality control checks including the assessment of cell viability, RNA integrity, and sequencing depth. Use established thresholds, such as a minimum of 200 detected genes per cell and a maximum of 5% mitochondrial gene expression to filter cells. Employ the Seurat package for preprocessing and normalization, using the 'LogNormalize' method with a scale factor of 10,000.",
            "Reference Source": {
                "id1": {
                    "GSE205492": [
                        "GSM6213616"
                    ]
                }
            }
        },
        "step 2": {
            "implementation details": "Identify specific cell types within the immune microenvironment using the Seurat package. Perform clustering analysis based on the expression profiles using the Louvain algorithm with a resolution parameter set to 0.5. Additionally, utilize the first 20 principal components for clustering. Visualize the clustering outcomes with UMAP plots to elucidate the distribution of immune cell types. Validate the clustering results by comparing them with known marker gene expression profiles for immune cell types.",
            "Reference Source": {
                "id1": {
                    "Seurat Protocol": [
                        "https://satijalab.org/seurat/articles/pbmc3k_tutorial.html"
                    ]
                }
            }
        },
        "step 3": {
            "implementation details": "Correlate single-cell sequencing data with bulk RNA sequencing findings from datasets GSE21122, GSE159659, and GSE30929. Use marker genes identified from the bulk RNA-seq analysis to cross-reference with the single-cell data. Test for concordance between the two datasets by identifying overlapping gene expression patterns and assessing the expression levels of key immune markers. Utilize statistical tests, such as Spearman correlation with a threshold for significance set at p < 0.05, to quantify the relationships between single-cell and bulk data expressions. Address any discrepancies by performing a differential expression analysis to understand the similarities and differences in immune cell representation.",
            "Reference Source": {
                "id1": {
                    "GSE21122": [
                        "GSM528276"
                    ],
                    "GSE159659": [
                        "GSM4837048"
                    ],
                    "GSE30929": [
                        "GSM766533"
                    ]
                }
            }
        }
    }
}